ALAN MERTZ — Lobbyist Profile | Poliscope

ALAN MERTZ

Filings

Clients

Firms

Years active

2018–2023

Associated filing income

$912,615

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
NEOGENOMICS LABORATORIES	21	2018–2023

Lobbying firms

Firm	Filings	Years
NEOGENOMICS LABORATORIES	21	2018–2023

Bills explicitly cited in this lobbyist’s assigned issues (14)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 8188

Mutual Fund Litigation Reform Act

Client: NEOGENOMICS LABORATORIES · Firm: NEOGENOMICS LABORATORIES

Open original LDA filing ↗

Cited source text

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404 Saving Access to Laboratory Services Act, S. 4449, HR 8188

H.R. 8188

Mutual Fund Litigation Reform Act

Client: NEOGENOMICS LABORATORIES · Firm: NEOGENOMICS LABORATORIES

Open original LDA filing ↗

Cited source text

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404 Saving Access to Laboratory Services Act, S. 4449, HR 8188

Original LDA source filings (21)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2023 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Validating Accurate Leading Edge IVCT Development Act

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2023 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Source: Senate LDA

Show 17 more original filings

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2022 · second_quarter · Q2

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2022 · first_quarter · Q1

Firm income: $60,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2021 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2021 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2021 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2021 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2020 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2020 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2020 · second_quarter · Q2

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2020 · first_quarter · Q1

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2019 · fourth_quarter · Q4

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Laboratory Access for Beneficiaries Act (LAB Act) HR 3584 Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2019 · third_quarter · Q3

Firm income: $40,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Laboratory Access for Beneficiaries Act (LAB Act) HR 3584 Verifying Accurate Leading-Edge IVCT Development Act (VALID Act), Draft Legislation

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2019 · second_quarter · Q2

Firm income: $52,615Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Diagnostic Accuracy and Innovation Act

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2019 · first_quarter · Q1

Firm income: $45,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Diagnostic Accuracy and Innovation Act

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2018 · fourth_quarter · Q4

Firm income: $35,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Diagnostic Accountability and Innovation Act (DAIA) Protecting Access to Medicare Act (PAMA) Verifying Leading Edge IVCT Development Act (VALID)

Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2018 · third_quarter · Q3

Firm income: $20,000Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Diagnostic Accountability and Innovation Act (DAIA) Protecting Access to Medicare Act (PAMA)

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

NEOGENOMICS LABORATORIES via NEOGENOMICS LABORATORIES

2018 · third_quarter · RR

Firm income: —Client expense: —Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

MED

Medical/Disease Research/Clinical Labs

Diagnostic Innovation and Accountability Act (DIAA) Protecting Access to Medicare Act (PAMA)